Comparable Attenuation of Sympathetic Nervous System Activity in Obese Subjects with Normal Glucose Tolerance, Impaired Glucose Tolerance, and Treatment Naive Type 2 Diabetes following Equivalent Weight Loss

被引:22
|
作者
Straznicky, Nora E. [1 ]
Grima, Mariee T. [1 ]
Sari, Carolina I. [1 ]
Lambert, Elisabeth A. [1 ,2 ,3 ]
Phillips, Sarah E. [1 ]
Eikelis, Nina [1 ]
Mariani, Justin A. [4 ,5 ]
Kobayashi, Daisuke [1 ]
Hering, Dagmara [1 ]
Dixon, John B. [1 ,6 ]
Lambert, Gavin W. [1 ,5 ]
机构
[1] Baker IDI Heart & Diabet Inst, Human Neurotransmitters Lab, Melbourne, Vic, Australia
[2] Monash Univ, Dept Physiol, Melbourne, Vic, Australia
[3] Univ Melbourne, Dept Physiol, Melbourne, Vic, Australia
[4] Baker IDI Heart & Diabet Inst, Heart Failure Res Grp, Melbourne, Vic, Australia
[5] Monash Univ, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia
[6] Monash Univ, Dept Primary Hlth Care, Melbourne, Vic, Australia
来源
FRONTIERS IN PHYSIOLOGY | 2016年 / 7卷
基金
澳大利亚国家健康与医学研究理事会;
关键词
sympathetic nervous system; obesity; weight loss; hypocaloric diet; glucose tolerance; hyperinsulinemia; type; 2; diabetes; ARTERIAL BAROREFLEX CONTROL; BETA-CELL FUNCTION; NEURAL ACTIVATION; PLASMA NOREPINEPHRINE; RISK-FACTORS; HEART-RATE; INSULIN; LEPTIN; GAIN; HYPERTENSION;
D O I
10.3389/fphys.2016.00516
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Background and Purpose: Elevated sympathetic nervous system (SNS) activity is a characteristic of obesity and type 2 diabetes (T2D) that contributes to target organ damage and cardiovascular risk. In this study we examined whether baseline metabolic status influences the degree of sympathoinhibition attained following equivalent dietary weight loss. Methods: Un-medicated obese individuals categorized as normal glucose tolerant (NGT, n = 15), impaired glucose tolerant (IGT, n = 24), and newly-diagnosed T2D (n = 15) consumed a hypocaloric diet (29% fat, 23% protein, 45% carbohydrate) for 4-months. The three groups were matched for baseline age (56 +/- 1 years), body mass index (BMI, 32.9 +/- 0.7 kg/m(2)), and gender. Clinical measurements included whole-body norepinephrine kinetics, muscle sympathetic nerve activity (MSNA, by microneurography), spontaneous cardiac baroreflex sensitivity (BRS), and oral glucose tolerance test. Results: Weight loss averaged -7.5 +/- 0.8, -8.1 +/- 0.5, and -8.0 +/- 0.9% of body weight in NGT, IGT, and T2D groups, respectively. T2D subjects had significantly greater reductions in fasting glucose, 2-h glucose and glucose area under the curve (AUC(0-120)) compared to NGT and IGT (group effect, P < 0.001). Insulinogenic index decreased in IGT and NGT groups and increased in T2D (group x time, P = 0.04). The magnitude of reduction in MSNA (-7 +/- 3, -8 +/- 4, -15 +/- 4 burst/100 hb, respectively) and whole-body norepinephrine spillover rate (-28 +/- 8, -18 +/- 6, and -25 +/- 7%, respectively), time effect both P < 0.001, did not differ between groups. After adjustment for age and change in body weight, Delta insulin AUC(0-120) was independently associated with reduction in arterial norepinephrine concentration, whilst Delta LDL-cholesterol and improvement in BRS were independently associated with decrease in MSNA. Conclusions: Equivalent weight loss through hypocaloric diet is accompanied by similar sympathoinhibition in matched obese subjects with different baseline glucose tolerance. Attenuation of hyperinsulinemia and hyperlipidemia, rather than glycemic indices, is associated with reduction in SNS activity following weight loss intervention.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
    Mari, Andrea
    Bagger, Jonatan I.
    Ferrannini, Ele
    Holst, Jens J.
    Knop, Filip K.
    Vilsboll, Tina
    PLOS ONE, 2013, 8 (09):
  • [32] Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in obese Argentinean children and adolescents
    Mazza, CS
    Ozuna, B
    Krochik, AG
    Araujo, MB
    JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, 2005, 18 (05): : 491 - 498
  • [33] Effects of agar (kanten) diet on obese patients with impaired glucose tolerance and type 2 diabetes
    Maeda, H
    Yamamoto, R
    Hirao, K
    Tochikubo, O
    DIABETES OBESITY & METABOLISM, 2005, 7 (01): : 40 - 46
  • [34] Increased tumor necrosis factor-α system activity in obese subjects with impaired glucose tolerance.
    Dzienis-Straczkowska, S
    Straczkowski, M
    Stepien, A
    Szelachowska, M
    Kowalska, I
    Kinalska, I
    DIABETOLOGIA, 2001, 44 : A176 - A176
  • [35] Treatment with acarbose reduces postprandial hyperglycemia in subjects with impaired glucose tolerance or early untreated type 2 diabetes
    Byrne, MM
    Burhorn, M
    Goeke, B
    DIABETES, 2000, 49 : A341 - A341
  • [36] Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus
    Delorme, S
    Chiasson, JL
    CURRENT OPINION IN PHARMACOLOGY, 2005, 5 (02) : 184 - 189
  • [37] Abnormal lipid tolerance in subjects with impaired glucose tolerance and type 2 diabetes:: Relationship to intima-media thickness
    Henkel, E
    Leonhardt, W
    Metzler, W
    Böhmer, G
    Hanefeld, M
    ATHEROSCLEROSIS, 1999, 144 : 126 - 126
  • [38] Changes in glucose-elicited blood metabolite responses following weight loss and long term weight maintenance in obese individuals with impaired glucose tolerance
    Geidenstam, Nina
    Danielsson, Anders P. H.
    Spegel, Peter
    Ridderstrale, Martin
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 113 : 187 - 197
  • [39] Association between adiponectin, energy expenditure (EE) and lipid metabolism in subjects with normal glucose tolerance (NGT), impaired glucose tolerance (IGT) and Type 2 diabetes mellitus (DM)
    Gross, S
    Ott, P
    Köhler, C
    Hanefeld, M
    Matthies, K
    Bergmann, S
    Weck, M
    DIABETOLOGIA, 2004, 47 : A225 - A225
  • [40] Digestive, Anorectal, and Urogenital Functions in Patients with Type 2 Diabetes Mellitus, Impaired Glucose Tolerance and Normal Glucose Tolerance: Association with Autonomic Neuropathy
    Quast, Daniel R.
    Boronikolos, Georgios C.
    Menge, Bjoern A.
    Breuer, Thomas G. K.
    Schenker, Nina
    Meier, Juris J.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (05) : 299 - 306